MEROPENEM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C17H25N3O5S.3H2O
Molecular Weight	437.508
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.O.[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O

InChI

InChIKey=CTUAQTBUVLKNDJ-OBZXMJSBSA-N

InChI=1S/C17H25N3O5S.3H2O/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4;;;/h7-12,18,21H,5-6H2,1-4H3,(H,24,25);3*1H2/t7-,8-,9+,10+,11-,12-;;;/m1.../s1

HIDE SMILES / InChI

Molecular Formula	C17H25N3O5S
Molecular Weight	383.463
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://web.archive.org/web/20161209014344/http://www.ds-pharma.com:80/rd/new_value/meropen.html
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s036lbl.pdf |

Meropenem (generic name: meropenem hydrate) is a carbapenem antibiotic for injection showing a strong antibacterial activity to a wide range of bacteria strains from Gram-positive bacteria, Gram-negative bacteria to anaerobic bacteria. It is used as single agent therapy for the treatment of the following infections: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci. This drug also used in case of Intra-abdominal Infections for the treatment complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. In addition is used the treatment of bacterial meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (b-lactamase and non-b-lactamase-producing isolates), and Neisseria meningitides. The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coli and Pseudomonas aeruginosa; and PBPs 1, 2 and 4 of Staphylococcus aureus. Meropenem has significant stability to hydrolysis by β-lactamases, both penicillinases and cephalosporinases produced by Gram-positive and Gram-negative bacteria. Meropenem should not be used to treat methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-resistant Staphylococcus epidermidis (MRSE). Meropenem product with such superior effectiveness and safety has been approved for marketing by 100 countries or more in the world (as of March 2004) since its first launch in Italy in 1994.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 232 Target ID: CHEMBL2354204 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s036lbl.pdf	Inhibitor 8146

Conditions

Condition	Modality	Highest Phase	Product
Skin structure infections 18 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s036lbl.pdf	Curative	Approved 8307	MERREM Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection, USP (I.V.) and other antibacterial drugs, Meropenem for injection, USP (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Meropenem for injection, USP (I.V.) is useful as presumptive therapy in the indicated condition (e.g. intra-abdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity. For information regarding use in pediatric patients see Indications and Usage (1.1), (1.2) or (1.3); Dosage and Administration (2.3), Adverse Reactions (6.1), and Clinical Pharmacology (12.3). Meropenem for injection (I.V.) is a penem antibacterial indicated as single agent therapy for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) Complicated intra-abdominal infections (adult and pediatric patients). (1.2) Bacterial meningitis (pediatric patients 3 months of age and older only). (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection (I.V.) and other antibacterial drugs, Meropenem for injection (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis., 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species., 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species., 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis. Launch Date 8.3531517E11
Intra-abdominal infections 47 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s036lbl.pdf	Primary	Approved 8307	MERREM Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection, USP (I.V.) and other antibacterial drugs, Meropenem for injection, USP (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Meropenem for injection, USP (I.V.) is useful as presumptive therapy in the indicated condition (e.g. intra-abdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity. For information regarding use in pediatric patients see Indications and Usage (1.1), (1.2) or (1.3); Dosage and Administration (2.3), Adverse Reactions (6.1), and Clinical Pharmacology (12.3). Meropenem for injection (I.V.) is a penem antibacterial indicated as single agent therapy for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) Complicated intra-abdominal infections (adult and pediatric patients). (1.2) Bacterial meningitis (pediatric patients 3 months of age and older only). (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection (I.V.) and other antibacterial drugs, Meropenem for injection (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis., 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species., 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species., 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis. Launch Date 8.3531517E11
Bacterial meningitis 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s036lbl.pdf	Curative	Approved 8307	MERREM Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection, USP (I.V.) and other antibacterial drugs, Meropenem for injection, USP (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Meropenem for injection, USP (I.V.) is useful as presumptive therapy in the indicated condition (e.g. intra-abdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity. For information regarding use in pediatric patients see Indications and Usage (1.1), (1.2) or (1.3); Dosage and Administration (2.3), Adverse Reactions (6.1), and Clinical Pharmacology (12.3). Meropenem for injection (I.V.) is a penem antibacterial indicated as single agent therapy for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) Complicated intra-abdominal infections (adult and pediatric patients). (1.2) Bacterial meningitis (pediatric patients 3 months of age and older only). (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection (I.V.) and other antibacterial drugs, Meropenem for injection (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis., 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species., 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species., 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis. Launch Date 8.3531517E11

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B2-0044	http://www.3bsc.com/index/pro_info.php?id=19400
3B Scientific (Wuhan) Corp	3B1-01460	http://www.3bsc.com/index/pro_info.php?id=21672
3B Scientific (Wuhan) Corp	3B2-1156	http://www.3bsc.com/index/pro_info.php?id=54872
AEchem Scientific Corp., USA	AE1-006420	http://www.aechemsc.com/info_products/AE1-006420.php
AHH Chemical co.,ltd	API-1041	http://www.ahhchemical.com/product/API-1041.html
AHH Chemical co.,ltd	MT-53511	http://www.ahhchemical.com/product/MT-53511.html
AK Scientific, Inc. (AKSCI)	J10087	http://www.aksci.com/item_detail.php?cat=J10087
Aaron Chemicals	AR00397K	http://www.aaronchem.com/96036-03-2
Achemo Scientific Limited	AC-13275	http://www.achemo.com/search/?Keyword= 96036-03-2
Achemtek	0101-001564	http://www.achemtek.com/96036-03-2
Acorn PharmaTech	ACN-048182	http://www.acornpharmatech.com/
Adooq BioScience	A10569	https://www.adooq.com/meropenem.html
Ambeed	A647306	https://www.ambeed.com/products/96036-03-2.html
ApexBio Technology	A5124	http://www.apexbt.com/meropenem-22012.html
AstaTech, Inc.	45000	http://www.astatechinc.com/CPSResult.php?CRNO=1382
Aurum Pharmatech LLC	S-3680	http://www.Aurumpharmatech.com/Product/ProductDetails/S_3680
AvaChem Scientific	1716	http://www.avachem.com/productSearch.asp?1716
BLD Pharm	BD23263	http://www.bldpharm.com/products/96036-03-2.html
BioSynth	M-2780	https://www.biosynth.com/products/biochemistry/culture-media-additives/products/M-2780.html
CSNpharm	CSN13108	https://www.csnpharm.com/products/meropenem.html
Capot Chemical	17275	http://www.capotchem.com/en/17275.htm
Capot Chemical	PubChem17275	http://www.capotchem.com/en/17275.htm
Chem Scene	CS-1865	http://www.chemscene.com/96036-03-2.html
ChemMol	2100052	http://www.chemmol.com/chemmol/2100052.html
ChemMol	97602823	http://www.chemmol.com/chemmol/97602823.html
Chemspace	CSSB00020615435	https://chem-space.com/CSSB00020615435
Chiralblock Biosciences	CB11530	http://www.chiralblock.com/products/96036-03-2.html
Clearsynth	CS-M-58087	http://www.clearsynth.com/en/CSM58087.html
DC Chemicals	DCAPI1395	http://www.dcchemicals.com//product_show-Meropenem.html
Glentham Life Sciences	GP7412	http://www.glentham.com/products/product/GP7412/
Hairui	HR124915	http://www.hairuichem.com/en/product/119478-56-7.html
Hairui	HR127380	http://www.hairuichem.com/en/product/96036-03-2.html
Lab Network	LN00174071	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00174071
Matrix Scientific	75811	https://www.matrixscientific.com/075811.html
MedChem Express	HY-13678	https://www.medchemexpress.com/meropenem.html
MuseChem	A000590	https://www.musechem.com/product/A000590.html
OChem	7522	http://www.ocheminc.com/index.php?act=psearch&pid=036M032
Oakwood	M05727	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=130064&ExtHyperLink=1
Oakwood	36531	http://www.oakwoodchemical.com/p-31256-036531.aspx
Sinfoo Biotech	S061047	http://www.sinfoobiotech.com/product/1064450
Smolecule	S535012	http://www.smolecule.com/products/s535012
Smolecule	S795550	https://www.smolecule.com/products/s795550
TCI (Tokyo Chemical Industry)	M2279	http://www.tcichemicals.com/eshop/en/us/commodity/M2279/index.html
THE BioTek	bt-274921	https://www.thebiotek.com/product/inhibitors/bt-274921
THE BioTek	bt-289487	https://www.thebiotek.com/product/others/bt-289487
eNovation Chemicals	D518319	https://www.enovationchem.com/ProductDetails.asp?ProductID=D518319

PubMed

Title	Date	PubMed
Investigation of synergism of meropenem and ciprofloxacin against Pseudomonas aeruginosa and Acinetobacter strains isolated from intensive care unit infections.	2001	11760161
Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.	2001	11735679
[Antibiotic therapy of cystic fibrosis in children].	2001	11544748
[Antimicrobial activities and mechanisms of carbapenem resistance in clinical isolates of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter spp].	2001 Aug	11558128
[The high level resistance to carbapenems in Acinetobacter baumannii is a multifactorial problem].	2001 Aug-Sep	11747791
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].	2001 Dec	11856982
Antimicrobial susceptibility of respiratory isolates of Enterobacteriaceae and Staphylococcus aureus in Italy: incidence and trends over the period 1997-1999.	2001 Dec	11837636
Empirical monotherapy with meropenem in serious bacterial infections in children.	2001 Dec	11825008
Comparative in-vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000.	2001 Dec	11810597
Survey of antibiotic resistance in Pseudomonas aeruginosa by The Tokyo Johoku Association of Pseudomonas Studies.	2001 Dec	11810595
Meropenem pharmacokinetics in children and adolescents receiving hemodialysis.	2001 Dec	11793091
Unit differences in pathogen occurrence arising from the MYSTIC program European database (1997-2000).	2001 Dec	11777658
MYSTIC program: summary of European data from 1997 to 2000.	2001 Dec	11777657
Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA).	2001 Dec	11777656
Determining the value of antimicrobial surveillance programs.	2001 Dec	11777655
MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) conference. Hamburg, Germany, 10 May 2001.	2001 Dec	11777654
In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa.	2001 Dec	11738346
A novel metallo-beta-lactamase, Mbl1b, produced by the environmental bacterium Caulobacter crescentus.	2001 Dec 14	11749954
[In vitro and in vivo activities of panipenem against penicillin-resistant Streptococcus pneumoniae].	2001 Jul	11560055
Use of broad spectrum antibiotics in six non-university Swiss hospitals.	2001 Jul 28	11582634
Ertapenem: a new carbapenem.	2001 Jun	11772242
[A case of eosinophilic pneumonia possibly due to ifenprodil].	2001 Nov	11855087
[Comparative antibacterial activity of carbapenems against P. aeruginosa (1)].	2001 Nov	11828603
Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!	2001 Nov	11750171
In vitro and in vivo activities of meropenem and comparable antimicrobial agents against Haemophilus influenzae, including beta-lactamase-negative ampicillin-resistant strains.	2001 Nov	11679563
National shortages of antimicrobial agents: results of 2 surveys from the Infectious Diseases Society of America Emerging Infections Network.	2001 Nov 1	11588695
Influence of in-vivo endotoxin liberation on anti-anaerobic antimicrobial efficacy.	2001 Oct	11760215
Failure of cefotaxime and meropenem to eradicate meningitis caused by an intermediately susceptible Streptococcus pneumoniae strain.	2001 Oct	11757981
[A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections].	2001 Sep	11758237
[Susceptibility to penicillin and 13 antimicrobial agents in erythromycin-resistant viridans group streptococci isolated from blood cultures].	2001 Sep	11753449
[Pyogenic sacroiliitis in pregnancy].	2001 Sep	11729713
[Antimicrobial activities of carbapenems and fourth generation cephems against clinically isolated strains].	2001 Sep	11729712
Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998.	2001 Sep	11714042
Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits.	2001 Sep	11683247
Isolation and culture of airway epithelial cells from chronically infected human lungs.	2001 Sep	11669281
Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting.	2001 Sep	11533004
Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety.	2001 Sep 3	11527740
Comparative in vitro activity of isepamicin and other antibiotics against gram-negative bacilli from intensive care units (ICU) in Belgium.	2001 Sep-Oct	11774843
Effects of cefepime and meropenem on the gastrointestinal colonization of surgical patients by Candida albicans.	2001 Sep-Oct	11561137
Antibiotic persistence: the role of spontaneous DNA repair response.	2001 Winter	11822773
Use of Etests with carbapenems for Gram-negative rods producing beta-lactamases.	2002 Feb	11850170
Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients.	2002 Feb	11850162
Carbapenem-resistant Acinetobacter and role of curtains in an outbreak in intensive care units.	2002 Feb	11846537
In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany.	2002 Feb	11815589
Meropenem stability to beta-lactamase hydrolysis and comparative in vitro activity against several beta-lactamase-producing Gram-negative strains.	2002 Feb	11815587
Acute necrotizing gastritis by Escherichia coli in a severely neutropenic patient.	2002 Jan	11801485
Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital.	2002 Jan	11751769
Primary liver abscess caused by one clone of Klebsiella pneumoniae with two colonial morphotypes and resistotypes.	2002 Jan	11749761
Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).	2002 Mar	11864948
Antibiotic-resistant gram-negative organisms in pediatric chronic-care facilities.	2002 Mar 15	11850860

Patents

Sample Use Guides

In Vivo Use Guide

Adult Patients: The recommended dose of MERREM I.V. is 500 mg given every 8 hours for skin and skin structure infections and 1 gram given every 8 hours for intra-abdominal infections. When treating complicated skin and skin structure infections caused by P.aeruginosa, a dose of 1 gram every 8 hours is recommended. Pediatric Patients 3 Months of Age and Older: For pediatric patients 3 months of age and older, the MERREM I.V. dose is 10 mg/kg, 20 mg/kg or 40 mg/kg every 8 hours (maximum dose is 2 grams every 8 hours), depending on the type of infection (complicated skin and skin structure, intra-abdominal or meningitis). Pediatric patients weighing over 50 kg should be administered MERREM I.V. at a dose of 500 mg every 8 hours for complicated skin and skin structure infections, 1 gram every 8 hours for intra-abdominal infections and 2 grams every 8 hours for meningitis. MERREM I.V. should be given as intravenous infusion over approximately 15 minutes to 30 minutes or as an intravenous bolus injection (5 mL to 20 mL) over approximately 3 minutes to 5 minutes. There is limited safety data available to support the administration of a 40 mg/kg (up to a maximum of 2 grams) bolus dose.

Route of Administration: Intravenous

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 16 19:43:07 UTC 2022` Edited by `admin` on `Fri Dec 16 19:43:07 UTC 2022`
Record UNII	FV9J3JU8B1
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MEROPENEM

Official Name

English

ICI 194,660

Code

English

MERREM I.V.

Brand Name

English

MERONEM

Brand Name

English

MEROPENEM [USAN]

Common Name

English

MEROPENEM TRIHYDRATE

Common Name

English

NSC-759621

Code

English

Meropenem trihydrate [WHO-DD]

Common Name

English

MEROPENEM HYDRATE [JAN]

Common Name

English

MEROPENEM [VANDF]

Common Name

English

(4R,5S,6S)-3-[[(3S,5S)-5-(Dimethylcarbamoyl)-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, trihydrate

Common Name

English

MEROPENEM HYDRATE

Common Name

English

MEROPENEM [USP-RS]

Common Name

English

MEROPENEM (AS TRIHYDRATE)

Common Name

English

MEROPENEM [USP MONOGRAPH]

Common Name

English

MEROPENEM TRIHYDRATE [MI]

Common Name

English

MEROPENEM [MART.]

Common Name

English

SM-7338

Code

English

MERREM

Brand Name

English

MEROPENEM TRIHYDRATE [EP MONOGRAPH]

Common Name

English

MEROPENEM [ORANGE BOOK]

Common Name

English

VABOMERE COMPONENT MEROPENEM

Brand Name

English

MEROPENEM COMPONENT OF CARBAVANCE

Brand Name

English

1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID, 3-((5-((DIMETHYLAMINO)CARBONYL)-3-PYRROLIDINYL)THIO)-6-(1-HYDROXYETHYL)-4-METHYL-7-OXO-, TRIHYDRATE, (4R-(3(3S*,5S*),4.ALPHA.,5.BETA.,6.BETA.(R*)))-

Common Name

English

ICI-194660

Code

English

MEROPENEM [USP IMPURITY]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QJ01DH02

Created by admin on Fri Dec 16 19:43:08 UTC 2022 , Edited by admin on Fri Dec 16 19:43:08 UTC 2022

NCI_THESAURUS

C260

Created by admin on Fri Dec 16 19:43:08 UTC 2022 , Edited by admin on Fri Dec 16 19:43:08 UTC 2022

NDF-RT

N0000175496

Created by admin on Fri Dec 16 19:43:08 UTC 2022 , Edited by admin on Fri Dec 16 19:43:08 UTC 2022

WHO-ATC

J01DH02

Created by admin on Fri Dec 16 19:43:07 UTC 2022 , Edited by admin on Fri Dec 16 19:43:07 UTC 2022

WHO-ATC

J01DH52

Created by admin on Fri Dec 16 19:43:07 UTC 2022 , Edited by admin on Fri Dec 16 19:43:07 UTC 2022

FDA ORPHAN DRUG

130799

Created by admin on Fri Dec 16 19:43:08 UTC 2022 , Edited by admin on Fri Dec 16 19:43:08 UTC 2022

LIVERTOX

NBK547861

Created by admin on Fri Dec 16 19:43:08 UTC 2022 , Edited by admin on Fri Dec 16 19:43:08 UTC 2022

Code System Code Type Description

PUBCHEM

441129

Created by admin on Fri Dec 16 19:43:08 UTC 2022 , Edited by admin on Fri Dec 16 19:43:08 UTC 2022

PRIMARY

DRUG BANK

DB00760

Created by admin on Fri Dec 16 19:43:07 UTC 2022 , Edited by admin on Fri Dec 16 19:43:07 UTC 2022

PRIMARY

WIKIPEDIA

MEROPENEM

Created by admin on Fri Dec 16 19:43:08 UTC 2022 , Edited by admin on Fri Dec 16 19:43:08 UTC 2022

PRIMARY

LACTMED

Meropenem

Created by admin on Fri Dec 16 19:43:08 UTC 2022 , Edited by admin on Fri Dec 16 19:43:08 UTC 2022

PRIMARY

ChEMBL

CHEMBL127

Created by admin on Fri Dec 16 19:43:07 UTC 2022 , Edited by admin on Fri Dec 16 19:43:07 UTC 2022

PRIMARY

USAN

BB-52

Created by admin on Fri Dec 16 19:43:08 UTC 2022 , Edited by admin on Fri Dec 16 19:43:08 UTC 2022

PRIMARY

FDA UNII

FV9J3JU8B1

Created by admin on Fri Dec 16 19:43:08 UTC 2022 , Edited by admin on Fri Dec 16 19:43:08 UTC 2022

PRIMARY

RS_ITEM_NUM

1392454

Created by admin on Fri Dec 16 19:43:08 UTC 2022 , Edited by admin on Fri Dec 16 19:43:08 UTC 2022

PRIMARY

MERCK INDEX

M7240

Created by admin on Fri Dec 16 19:43:08 UTC 2022 , Edited by admin on Fri Dec 16 19:43:08 UTC 2022

PRIMARY

Merck Index

EVMPD

SUB21617

Created by admin on Fri Dec 16 19:43:07 UTC 2022 , Edited by admin on Fri Dec 16 19:43:07 UTC 2022

PRIMARY

EPA CompTox

DTXSID10274179

Created by admin on Fri Dec 16 19:43:08 UTC 2022 , Edited by admin on Fri Dec 16 19:43:08 UTC 2022

PRIMARY

MESH

C059500

Created by admin on Fri Dec 16 19:43:08 UTC 2022 , Edited by admin on Fri Dec 16 19:43:08 UTC 2022

PRIMARY

DAILYMED

FV9J3JU8B1

Created by admin on Fri Dec 16 19:43:07 UTC 2022 , Edited by admin on Fri Dec 16 19:43:07 UTC 2022

PRIMARY

NSC

759621

Created by admin on Fri Dec 16 19:43:08 UTC 2022 , Edited by admin on Fri Dec 16 19:43:08 UTC 2022

PRIMARY

CHEBI

6770

Created by admin on Fri Dec 16 19:43:07 UTC 2022 , Edited by admin on Fri Dec 16 19:43:07 UTC 2022

PRIMARY

DRUG CENTRAL

1709

Created by admin on Fri Dec 16 19:43:08 UTC 2022 , Edited by admin on Fri Dec 16 19:43:08 UTC 2022

PRIMARY

RXCUI

29561

Created by admin on Fri Dec 16 19:43:08 UTC 2022 , Edited by admin on Fri Dec 16 19:43:08 UTC 2022

PRIMARY

RxNorm

CHEBI

43968

Created by admin on Fri Dec 16 19:43:07 UTC 2022 , Edited by admin on Fri Dec 16 19:43:07 UTC 2022

PRIMARY

NCI_THESAURUS

C1160

Created by admin on Fri Dec 16 19:43:08 UTC 2022 , Edited by admin on Fri Dec 16 19:43:08 UTC 2022

PRIMARY

CAS

119478-56-7

Created by admin on Fri Dec 16 19:43:07 UTC 2022 , Edited by admin on Fri Dec 16 19:43:07 UTC 2022

PRIMARY

Related Record Type Details


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					ZWJ2Y6JZWY

OAT-3

TRANSPORTER -> SUBSTRATE


					YOP6PX0BAO

MEROPENEM ANHYDROUS

ANHYDROUS->SOLVATE


					FV9J3JU8B1

MEROPENEM

EXCRETED UNCHANGED

Comments:

Meropenem: approximately 40–60% of dose was excreted unchanged within 24 to 48 hours with a further 28% recovered as the microbiologically inactive hydrolysis product; fecal elimination accounts for ~2% of dose.


					YOP6PX0BAO

MEROPENEM ANHYDROUS

PARENT -> SALT/SOLVATE


					I81U7H57XI

OAT-1

TRANSPORTER -> SUBSTRATE

Related Record Type Details


					4MC3K7LDC6

MEROPENEM OPEN RING

IMPURITY -> PARENT

Comments:

correction factor: for the calculation of content, multiply the peak area of impurity A by 1.6

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					G6636F29A1

MEROPENEM DIMER

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:

Related Record Type Details


					YOP6PX0BAO

MEROPENEM ANHYDROUS

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Volume of Distribution	PHARMACOKINETIC

Biological Half-life	PHARMACOKINETIC

Details

SMILES

InChI

DescriptionSources: https://web.archive.org/web/20161209014344/http://www.ds-pharma.com:80/rd/new_value/meropen.htmlCurator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s036lbl.pdf |

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://web.archive.org/web/20161209014344/http://www.ds-pharma.com:80/rd/new_value/meropen.html
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s036lbl.pdf |